Third Opinion Trial Synopsis
This study is looking at how well a medicine called selinexor works when combined with other treatments for a type of cancer called multiple myeloma. The study will include patients whose current treatment is not working well enough, and they will be split into 3 groups depending on the medicine they are currently taking. The patients will receive the new treatment until their cancer gets worse, they have bad side effects, or they decide to stop.

Trial Summary
This is a prospective, 2-arm (with an additional exploratory arm), open-label, multicenter study looking at the response rate of patients receiving selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide. Multiple Myeloma patients with documented disease progression or refractory disease while on current treatment with any carfilzomib-containing regimen (arm 1), any pomalidomide-containing regimen (arm 2) or any daratumumab-containing regimen (exploratory arm) will be included in the study. Patients will be assigned to the respective groups according to their current treatment. If a subject has received more than one of the above therapies, then assignment will be made at their physician's discretion (e.g treatment decision can be made based upon patient and physician preferred tolerance.). Patients will receive treatment until progressive disease (PD), death, toxicity that cannot be managed by standard of care, or withdrawal, whichever occurs first.